• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.

作者信息

Ahmed Gulrayz, Alsouqi Aseel, Szabo Aniko, Samples Laura, Shadman Mazyar, Awan Farrukh T, Rojek Alexandra E, Riedell Peter A, Iqbal Madiha, Fenske Timothy S, Kharfan-Dabaja Mohamed A, Ito Sawa, Hamadani Mehdi

机构信息

Division of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

出版信息

Blood Adv. 2024 Jul 9;8(13):3528-3531. doi: 10.1182/bloodadvances.2023012255.

DOI:10.1182/bloodadvances.2023012255
PMID:38701405
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11261102/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf9e/11261102/c860d77be22b/BLOODA_ADV-2023-012255-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf9e/11261102/c860d77be22b/BLOODA_ADV-2023-012255-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf9e/11261102/c860d77be22b/BLOODA_ADV-2023-012255-gr1.jpg

相似文献

1
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.嵌合抗原受体T细胞疗法治疗继发中枢神经系统受累的套细胞淋巴瘤：一项多中心经验。
Blood Adv. 2024 Jul 9;8(13):3528-3531. doi: 10.1182/bloodadvances.2023012255.
2
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.布雷西尤卡布他赛自体CAR T细胞疗法联合BTK抑制剂治疗复发伴中枢神经系统受累套细胞淋巴瘤的疗效与安全性。
Leuk Lymphoma. 2024 May;65(5):669-673. doi: 10.1080/10428194.2024.2304622. Epub 2024 Jan 22.
3
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.携手向善：嵌合抗原受体T细胞与布鲁顿酪氨酸激酶抑制剂在合并中枢神经系统受累的套细胞淋巴瘤中的应用
Leuk Lymphoma. 2024 May;65(5):546-547. doi: 10.1080/10428194.2024.2320833. Epub 2024 Feb 29.
4
Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.嵌合抗原受体T细胞疗法治疗中枢神经系统受累的大B细胞淋巴瘤患者：一项系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e142-e151. doi: 10.1016/j.clml.2023.12.012. Epub 2024 Jan 12.
5
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.纳入CD28和TLR2细胞内结构域的第三代CD19嵌合抗原受体T细胞治疗合并中枢神经系统受累的B细胞恶性肿瘤的疗效和安全性：一项关键试验的结果
J Transl Med. 2025 May 27;23(1):594. doi: 10.1186/s12967-025-06608-x.
6
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.嵌合抗原受体T细胞（CAR-T细胞）疗法治疗原发性和继发性中枢神经系统淋巴瘤：文献系统综述
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):15-21. doi: 10.1016/j.clml.2022.09.008. Epub 2022 Oct 7.
7
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.适应性制造的慢病毒抗CD20/抗CD19嵌合抗原受体T细胞用于复发难治性套细胞淋巴瘤的I/II期研究
J Clin Oncol. 2025 Mar 31:JCO2402158. doi: 10.1200/JCO-24-02158.
8
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.接受布雷西尤单抗自体白细胞治疗后病情进展的套细胞淋巴瘤患者的结局与管理
Br J Haematol. 2021 Jan;192(2):e38-e42. doi: 10.1111/bjh.17197. Epub 2020 Nov 5.
9
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.自体移植后继发性中枢神经系统淋巴瘤的嵌合抗原受体 T 细胞治疗：一例报告。
Medicine (Baltimore). 2021 Nov 5;100(44):e27733. doi: 10.1097/MD.0000000000027733.
10
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.tisagenlecleucel CAR T 细胞疗法治疗中枢神经系统淋巴瘤。
Blood. 2019 Sep 12;134(11):860-866. doi: 10.1182/blood.2019001694. Epub 2019 Jul 18.

引用本文的文献

1
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.复发/难治性中枢神经系统受累急性淋巴细胞白血病患者使用brexucabtagene autoleucel的疗效
Blood Adv. 2025 Aug 26;9(16):4081-4089. doi: 10.1182/bloodadvances.2024015779.
2
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.2025年我们如何采用细胞疗法治疗套细胞淋巴瘤：欧美视角
Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599-x.
3
Advances in CAR-T therapy for central nervous system tumors.

本文引用的文献

1
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.嵌合抗原受体 T 细胞疗法治疗伴有次级中枢神经系统受累的套细胞淋巴瘤的临床疗效和安全性。
Br J Haematol. 2023 Dec;203(5):774-780. doi: 10.1111/bjh.19037. Epub 2023 Aug 16.
2
Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter Study.全身照射、大剂量化疗及干细胞移植后套细胞淋巴瘤患者的长期生存：一项单中心研究
Cancers (Basel). 2023 Feb 3;15(3):983. doi: 10.3390/cancers15030983.
3
中枢神经系统肿瘤的嵌合抗原受体T细胞（CAR-T）疗法进展
Biomark Res. 2024 Nov 6;12(1):132. doi: 10.1186/s40364-024-00679-6.
4
Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤：系统评价和荟萃分析。
Front Immunol. 2024 Sep 6;15:1435127. doi: 10.3389/fimmu.2024.1435127. eCollection 2024.
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
在标准治疗实践中，Brexucabtagene Autoleucel 用于治疗复发或难治性套细胞淋巴瘤：来自美国淋巴瘤嵌合抗原受体 T 细胞治疗联盟的结果。
J Clin Oncol. 2023 May 10;41(14):2594-2606. doi: 10.1200/JCO.22.01797. Epub 2023 Feb 8.
4
CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse.用于治疗中枢神经系统复发的套细胞淋巴瘤的嵌合抗原受体T细胞疗法。
Blood Adv. 2023 Feb 14;7(3):375-378. doi: 10.1182/bloodadvances.2022008031.
5
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.伊布替尼相较于化疗可改善伴中枢神经系统复发的套细胞淋巴瘤患者的生存。
Blood. 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560.
6
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.KTE-X19 嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
7
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
8
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
9
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.套细胞淋巴瘤中枢神经系统累及：来自欧洲套细胞淋巴瘤网络的临床特征、预后因素和结局。
Ann Oncol. 2013 Aug;24(8):2119-23. doi: 10.1093/annonc/mdt139. Epub 2013 Apr 24.
10
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.原发性中枢神经系统淋巴瘤基线评估与反应标准标准化国际研讨会报告
J Clin Oncol. 2005 Aug 1;23(22):5034-43. doi: 10.1200/JCO.2005.13.524. Epub 2005 Jun 13.